Driehaus Capital Management’s Heron Therapeutics HRTX Stock Holding History

Driehaus Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-72,059	Closed	-$1.37M	–	591
2016 Q1	$1.37M	Sell	72,059 -85,267	-54%	-$1.68M	0.04%	335
2015 Q4	$4.2M	Buy	157,326 +57,013	+57%	+$1.52M	0.14%	170
2015 Q3	$2.45M	Sell	100,313 -74,089	-42%	-$2.47M	0.09%	253
2015 Q2	$5.43M	Sell	174,402 -8,720	-5%	-$164K	0.19%	124
2015 Q1	$2.66M	Sell	183,122 -560,625	-75%	-$6.32M	0.09%	277
2014 Q4	$7.48M	Sell	743,747 -115,734	-13%	-$945K	0.3%	82
2014 Q3	$7.16M	Buy	859,481 +80,206	+10%	+$747K	0.27%	93
2014 Q2	$9.6M	Sell	779,275 -144,956	-16%	-$1.73M	0.31%	73
2014 Q1	$12.9M	Buy	+924,231	New	+$12.3M	0.4%	57

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Driehaus Capital Management's HRTX Position: Q2 2016 in Review

Driehaus Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2016, closing a stake of 72,059 shares — an estimated $1.37M sold.

Driehaus Capital Management first reported a position in HRTX in Q1 2014 and held it in 9 quarters. The position peaked at $12.9M in Q1 2014. 92 funds tracked by Wall St. Rank hold HRTX as of Q2 2016.

Driehaus Capital Management reported no remaining Heron Therapeutics position as of Q2 2016 after selling out during the quarter.
Driehaus Capital Management sold 72,059 Heron Therapeutics shares in Q2 2016, an estimated $1.37M.
Driehaus Capital Management first reported a position in Heron Therapeutics in Q1 2014 and held it in 9 quarters.
Driehaus Capital Management's Heron Therapeutics position peaked at $12.9M in Q1 2014.
92 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2016.

Based on Driehaus Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.